Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

PGEN

Precigen Inc

Nov 21 • 04:00PM ET

3.88

-0.02 -0.51 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB VRTX REGN GILD ILMN INCY SRPT BLUE ARWR

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA IWC VFMO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.40	Insider Own	58.80%	Shs Outstand	353.81M	Perf Week	-20.00%
Market Cap	1.37B	Forward P/E	-	EPS next Y	-0.18	Insider Trans	-4.54%	Shs Float	145.76M	Perf Month	-8.71%
Enterprise Value	1.35B	PEG	-	EPS next Q	-0.08	Inst Own	31.63%	Short Float	23.55%	Perf Quarter	-2.51%
Income	-425.87M	P/S	217.57	EPS this Y	-136.17%	Inst Trans	5.58%	Short Ratio	5.33	Perf Half Y	183.21%
Sales	6.31M	P/B	32.79	EPS next Y	84.08%	ROA	-193.82%	Short Interest	34.33M	Perf YTD	246.43%
Book/sh	0.12	P/C	11.33	EPS next 5Y	-	ROE	-507.72%	52W High	5.22 -25.74%	Perf Year	387.68%
Cash/sh	0.34	P/FCF	-	EPS past 3/5Y	-0.39% 25.76%	ROIC	-306.52%	52W Low	0.65 495.73%	Perf 3Y	112.02%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-34.96% -46.64%	Gross Margin	10.14%	Volatility	10.10% 8.75%	Perf 5Y	-39.38%
Dividend TTM	-	EV/Sales	213.93	EPS Y/Y TTM	-155.65%	Oper. Margin	-1706.63%	ATR (14)	0.38	Perf 10Y	-88.91%
Dividend Ex-Date	-	Quick Ratio	3.95	Sales Y/Y TTM	59.20%	Profit Margin	-6750.13%	RSI (14)	46.34	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	4.04	EPS Q/Q	-1118.87%	SMA20	-6.34%	Beta	1.16	Target Price	8.50
Payout	-	Debt/Eq	2.35	Sales Q/Q	206.61%	SMA50	1.64%	Rel Volume	0.72	Prev Close	3.90
Employees	143	LT Debt/Eq	2.32	Earnings	Nov 13 AMC	SMA200	61.72%	Avg Volume	6.44M	Price	3.88
IPO	Aug 08, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1028.86% 484.40%	Trades		Volume	4,626,426	Change	-0.51%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-25	Upgrade	JP Morgan	Underweight → Neutral
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight	$7
Feb-25-21	Initiated	Stifel	Buy	$13
Feb-22-21	Initiated	Wells Fargo	Overweight	$14
Feb-18-21	Initiated	B. Riley Securities	Buy	$10
May-08-20	Initiated	H.C. Wainwright	Buy	$5

Nov-14-25 12:01AM	Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... (GuruFocus.com) +25.65%
Nov-13-25 04:05PM	Precigen Reports Third Quarter 2025 Financial Results and Business Updates (PR Newswire)
Nov-06-25 04:30PM	Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 (PR Newswire)
Oct-26-25 06:05AM	Precigen Reports Positive Long-Term Follow-Up Data for FDA-Approved RRP Therapy, PAPZIMEOS (Insider Monkey)
Oct-13-25 07:00AM	Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
07:23PM	Loading…
Sep-23-25 07:23PM	Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization (Insider Monkey)
Sep-20-25 02:43AM	Precigen, Inc. (PGEN) Bolsters Financial Standing to Enhance PAPZIMEOS Commercialization (Insider Monkey)
Sep-15-25 08:17AM	Precigen Signs a Credit Facility Agreement Worth $125 Million to Support PAPZIMEOS (Insider Monkey) -5.28%
Sep-12-25 03:41AM	4 years from clinic to approval Precigens unprecedented FDA nod and what comes next (Pharma Voice) -8.45%
Sep-11-25 03:31AM	Precigen's (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism (Insider Monkey)
Sep-07-25 08:23AM	These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts (Motley Fool)
Sep-03-25 07:00AM	Precigen Announces Up to $125 Million Non-Dilutive Financing (PR Newswire)
Sep-02-25 12:57AM	Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN) (Insider Monkey) +5.54%
Aug-28-25 10:00AM	INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug (Zacks)
Aug-26-25 08:39AM	Citizens JMP Raises PT on Precigen from $6 to $8, Keeps Outperform Rating (Insider Monkey) +7.04%
11:56PM	Loading…
Aug-25-25 11:56PM	H.C. Wainwright Remains Bullish on Precigen (PGEN) (Insider Monkey)
11:04AM	PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug (Zacks)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:05AM	Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright (PR Newswire)
Aug-20-25 12:22AM	Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment (Insider Monkey)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:42AM	FDA approves Papzimeos as first therapy for HPV-caused airway disease (Pharmaceutical Technology)
Aug-15-25 10:45AM	Hope Realized: FDA Approves Papzimeos for Adults with Recurrent Respiratory Papillomatosis (RRP) (Business Wire) +58.92%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:20AM	Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial (BioPharma Dive)
07:00AM	Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
May-14-25 04:05PM	Precigen Reports First Quarter 2025 Financial Results and Business Updates (PR Newswire) -5.19%
Apr-22-25 12:00PM	Patient Capital Management Q1 2025 Investment Review (Seeking Alpha) +11.68%
Apr-16-25 08:05AM	Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th (PR Newswire)
Mar-27-25 10:19AM	Is Precigen (PGEN) The Hot Biotech Stock Under $5? (InsiderMonkey)
06:23PM	Loading…
Mar-21-25 06:23PM	Precigen Inc (PGEN) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Mar-19-25 07:47PM	Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript (SeekingAlpha) +7.19%
06:25PM	Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Precigen Reports Full Year 2024 Financial Results and Business Updates (PR Newswire)
Mar-13-25 08:05AM	Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th (PR Newswire)
Mar-01-25 05:27PM	Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-25-25 08:05AM	FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 (PR Newswire)
Jan-13-25 07:00AM	Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire) -8.94%
Jan-09-25 08:30AM	Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-30-24 07:00AM	Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (PR Newswire) +28.47%
Dec-27-24 09:00AM	Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock (PR Newswire)
Nov-14-24 04:30PM	Precigen Reports Third Quarter 2024 Financial Results and Business Updates (PR Newswire) -7.11%
Nov-12-24 04:05PM	Precigen to Participate in the Stifel 2024 Healthcare Conference (PR Newswire) -5.04%
Sep-16-24 04:30PM	Precigen to Participate in the 2024 Cantor Global Healthcare Conference (PR Newswire)
Aug-14-24 04:05PM	Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates (PR Newswire)
01:54PM	Hedge Fund and Insider Trading News: Nelson Peltz, Jana Partners, Whitebox Advisors, Caxton Associates LP, Altium Capital, Soros Fund Management, Elliott Investment Management, Balyasny Asset Management, Precigen Inc (PGEN), Vulcan Materials Company (VMC), and More (Insider Monkey)
Aug-09-24 08:00AM	Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th (PR Newswire) -13.39%
Aug-07-24 09:30PM	Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock (PR Newswire) -12.59% +7.63%
Aug-06-24 04:04PM	Precigen Announces Proposed $30 Million Public Offering of Common Stock (PR Newswire)
04:01PM	Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch (PR Newswire)
Jul-23-24 08:01AM	Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch (PR Newswire)
Jun-03-24 09:30AM	Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response (PR Newswire) +11.43%
May-23-24 05:00PM	Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting (PR Newswire)
May-14-24 05:20PM	Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.11%
04:05PM	Precigen Reports First Quarter 2024 Financial Results and Business Updates (PR Newswire)
08:21AM	Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 04:05PM	Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting (PR Newswire)
Apr-24-24 10:20AM	Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting (PR Newswire)
09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Mar-28-24 04:05PM	Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th (PR Newswire)
Mar-27-24 08:20AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-20-24 10:07AM	Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 08:53PM	PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:31PM	Precigen Inc (PGEN) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Precigen Reports Full Year 2023 Financial Results and Business Updates (PR Newswire)
Mar-12-24 04:05PM	Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Mar-05-24 04:05PM	Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th (PR Newswire)
Feb-06-24 04:05PM	Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-16-24 08:05AM	Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission (PR Newswire)
Jan-08-24 08:30AM	Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.53%
Jan-02-24 12:40PM	Hedge Fund and Insider Trading News: David Einhorn, Bill Ackman, D. E. Shaw, Steve Cohen, Rob Citrone, Saba Capital, HighPeak Energy, Inc (HPK), Precigen Inc (PGEN), and More (Insider Monkey) +5.22%
Dec-18-23 04:05PM	Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.74%
Nov-29-23 04:05PM	Precigen to Participate in the JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-09-23 04:55PM	Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs (PR Newswire) -13.49%
Nov-07-23 04:05PM	Precigen to Participate in the Stifel 2023 Healthcare Conference (PR Newswire) +12.93%
Sep-19-23 04:05PM	Precigen to Participate in Upcoming Leading Investor and Industry Conferences (PR Newswire) -8.33% +6.06%
Aug-09-23 08:00AM	Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 (PR Newswire) +6.90%
07:05AM	Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval (PR Newswire)
Aug-03-23 04:05PM	Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th (PR Newswire) -6.67%
Jun-20-23 07:30AM	Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Jun-05-23 04:05PM	Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients (PR Newswire)
Jun-03-23 12:00PM	Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers (PR Newswire)
May-31-23 08:05AM	Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer (PR Newswire)
May-10-23 08:00AM	Precigen Reports First Quarter 2023 Financial Results and Business Updates (PR Newswire)
May-03-23 08:30AM	Precigen to Announce First Quarter 2023 Financial Results on May 10th (PR Newswire) +8.85%
Apr-26-23 04:05PM	Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy at the 2023 ASCO Annual Meeting (PR Newswire)
Apr-17-23 09:01AM	Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023 (PR Newswire) +10.48%
Apr-03-23 04:30PM	Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® (PR Newswire) +5.66% -8.04%
Mar-29-23 08:05AM	Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors (PR Newswire) +15.44%
Mar-28-23 08:05AM	Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium (PR Newswire)
Mar-06-23 04:05PM	Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (PR Newswire) +17.39%
Feb-07-23 08:00AM	Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response (News Direct)
Jan-30-23 02:34PM	Germantown's Precigen raises $75M to advance treatments for rare diseases (American City Business Journals)
Jan-27-23 04:05PM	Precigen Announces Closing of Public Offering of Common Stock (PR Newswire)
Jan-24-23 10:40PM	Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock (PR Newswire) -24.66%
04:05PM	Precigen Announces Proposed $75.0 Million Public Offering of Common Stock (PR Newswire)
04:01PM	Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (PR Newswire)
Jan-11-23 06:45PM	Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.64%
Jan-04-23 04:05PM	Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse Immunotherapy in Recurrent Respiratory Papillomatosis (PR Newswire) +5.41%
Dec-27-22 08:00AM	Precigens Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy (News Direct) -9.29%

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KIRK RANDAL J	Director	Nov 19 '25	Sale	4.47	1,086,153	4,855,104	7,434,384	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 20 '25	Sale	4.08	942,832	3,846,755	6,491,552	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 21 '25	Sale	3.83	937,308	3,589,890	5,554,244	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 20 '25	Proposed Sale	4.08	942,832	3,843,885		Nov 20 05:33 PM
KIRK RANDAL J	Director	Nov 19 '25	Proposed Sale	4.22	1,086,153	4,583,565		Nov 19 05:23 PM
KINDLER JEFFREY B	Director	Sep 30 '25	Sale	3.38	106,837	361,109	346,070	Oct 01 05:16 PM
KINDLER JEFFREY B	Director	Sep 29 '25	Sale	3.60	67,523	243,083	452,907	Oct 01 05:16 PM
KIRK RANDAL J	Director	Sep 30 '25	Sale	3.41	1,809,667	6,170,964	14,597,161	Sep 30 05:44 PM
KIRK RANDAL J	Director	Sep 30 '25	Proposed Sale	3.63	1,809,667	6,569,091		Sep 30 05:26 PM
Jeffrey Kindler	Director	Sep 30 '25	Proposed Sale	3.29	106,837	351,494		Sep 30 04:21 PM
Shah Rutul R	Chief Operating Officer	Sep 26 '25	Buy	3.40	2,000	6,800	405,959	Sep 30 04:07 PM
Tennant Phil	Chief Commercial Officer	Sep 29 '25	Buy	3.58	6,000	21,480	65,031	Sep 30 04:04 PM
Jeffrey Kindler	Director	Sep 29 '25	Proposed Sale	3.63	67,523	245,108		Sep 29 04:12 PM
Thomasian Harry Jr.	Chief Financial Officer	Sep 25 '25	Buy	3.62	8,284	29,988	465,694	Sep 26 05:01 PM
Thomasian Harry Jr.	Chief Financial Officer	Sep 26 '25	Buy	3.42	2,932	10,027	468,626	Sep 26 05:01 PM
KIRK RANDAL J	Director	Sep 19 '25	Sale	3.68	3,596,892	13,236,563	8,520,537	Sep 19 08:46 PM
KIRK RANDAL J	Director	Sep 18 '25	Sale	3.86	1,403,360	5,416,970	12,117,429	Sep 19 08:46 PM
KIRK RANDAL J	Director	Sep 19 '25	Proposed Sale	3.85	252	970		Sep 19 04:47 PM
KIRK RANDAL J	Director	Sep 18 '25	Proposed Sale	3.92	5,000,000	19,625,000		Sep 18 01:30 PM
AGEE NANCY H	Director	Sep 04 '25	Buy	4.60	15,000	69,000	217,841	Sep 05 05:46 PM
AGEE NANCY H	Director	Aug 28 '25	Buy	4.65	10,645	49,491	202,841	Aug 29 04:21 PM
AGEE NANCY H	Director	Aug 19 '25	Buy	3.20	15,360	49,152	192,196	Aug 29 04:21 PM
KIRK RANDAL J	Director	Mar 14 '25	Option Exercise	0.00	174,825	0	64,779,510	Mar 17 06:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

PGEN

Precigen Inc

Upgrade your FINVIZ experience